Summary
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash runway through 2029. OVID's lead asset, OV329, targets drug-resistant epilepsies with a differentiated safety profile; Phase 2 trials begin Q2 2026. Secondary asset OV4071, now in Phase 1, pivots toward the lucrative schizophrenia/psychosis market, offering pipeline diversification.
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions
Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and pharmacologic profile versus first-generation Sabril, targeting rare epilepsies. Phase 2 expansion includes POC studies in photosensitive seizures, treatment-resistant FOS, TSC-associated seizures, and infantile spasms, with key catalysts in 2026-2027.
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical research. The clinical-stage biotechnology company said the award highlights a multiyear partnership aimed at incorporating the lived experiences of clinical trial participants into the development of mental health treatments.
Ovid Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 1.32M | $2.15M | $3.28M | $1.12M | 52.15% |
 Jeffery Yorg Focus Partners Advisor Solutions LLC | 20,000 | $44,400 | $49,800 | $5,400 | 12.16% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 11,262 | $3,715.33 | $28,323.93 | $24,608.6 | 662.35% |
 Michael Byun SageView Advisory Group LLC | 44 | $72 | $108.9 | $36.9 | 51.25% |
| TK Taro Kuriyama Axq Capita LLP | 85,411 | $189,612 | $211,392.22 | $21,780.22 | 11.49% |
Ovid Therapeutics Inc. (OVID) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ovid Therapeutics Inc. ever had a stock split?
Ovid Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Margaret Alexander CEO | NASDAQ (NGS) Exchange | 690469101 CUSIP |
| US Country | 23 Employees | - Last Dividend | - Last Split | 5 May 2017 IPO Date |
Overview
Ovid Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and delivering impactful medicines for patients and families affected by epilepsies and seizure-related neurological disorders. Founded in 2014 and headquartered in New York, New York, Ovid Therapeutics has positioned itself as a trailblazer in the treatment of resistant epilepsies and other seizure-related conditions. The company's formidable dedication to addressing unmet medical needs in neurology through innovative therapeutic approaches is underscored by its collaborative efforts with leading medical institutions and pharmaceutical companies including Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, Graviton, and Marinus Pharmaceuticals, Inc. This extensive network of collaborations enhances Ovid's research capacity and accelerates the development of its novel therapeutic solutions, bringing hope to patients and families grappling with these challenging conditions.
Products and Services
Soticlestat (TAK-935/OV935)
A pioneering cholesterol 24 hydroxylase inhibitor, soticlestat is at the forefront of Ovid's pipeline, currently in Phase 3 clinical trials. Its development aims to provide a novel treatment option for patients with resistant epilepsies, demonstrating Ovid's commitment to addressing the needs of individuals with limited therapeutic options.
OV329
An emerging therapy, OV329 is a GABA aminotransferase inhibitor now in Phase 1 clinical trials. This therapeutic candidate targets seizures associated with tuberous sclerosis complex and infantile spasms, reflecting Ovid's focus on seizure-related disorders and its commitment to expanding treatment modalities for these conditions.
OV350
OV350, a novel small molecule direct activator of the KCC2 transporter, is in Phase 1 clinical trials. This innovative approach aims to treat various epilepsies, showcasing Ovid Therapeutics' continuous pursuit of breakthrough treatments in neurology.
OV815
This program targets mutations associated with KIF1A-associated neurological disorder (KAND), reflecting Ovid's dedication to developing treatments for rare neurological disorders. OV815 exemplifies the company's strategy to identify and advance therapies for conditions with high unmet medical need.
OV888 (GV101)
A highly selective rock2 inhibitor, OV888 is currently in a Phase 1 double-blind multiple-ascending dose trial. This underscores Ovid's commitment to exploring novel pathways and mechanisms for the treatment of neurological disorders.
OV825
Ovid is advancing OV825 as a potential candidate for treating the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome). This effort reflects the company's focus on addressing gaps in care for rare and underserved neurological conditions.
OV882
OV882 is a short hairpin RNA gene therapy candidate for the treatment of Angelman syndrome, a genetic disorder that affects the nervous system. By developing OV882, Ovid Therapeutics showcases its innovative approach to gene therapy as a mechanism to address neurological disorders at their genetic roots.
